Notice of Appeal
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]
NICE has received an appeal against the Final Draft Guidance on the above technology from the following organisations:
-
GSK
-
Myeloma UK
The appeal hearing originally scheduled for Thursday 2 November has been cancelled as the Final Draft Guidance has been withdrawn and the appraisal has been paused.
Please check the topic guidance page for further information and next steps.